United States Biotechnology & Medical Research

Rigel Pharmaceuticals Inc (RIGL)

Track

Rigel Pharmaceuticals experienced significant insider selling activity recently, totaling 408,350 USD in divestments over the past quarter. Director Kamil Ali-Jackson executed multiple planned sales during this period. These transactions occurred amidst a 53.3% stock price increase, following the company's latest earnings report which showed a slight miss in performance expectations.
Ticker: RIGL Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Rigel Pharmaceuticals Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 22 Jun 2026
Value US$1,041,116.40 | Price 59.05 | Shares 92,486 (-25.3%)
Proposed sale 22 Jun 2026
Value US$2,167,933.20 | Price 218.19 | Shares 79,403
Proposed sale 22 Jun 2026
Value US$87,500.00 | Price 35.00 | Shares 2,500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-24 2026-06-22 PlS Planned sale
3.2
Ali-Jackson Kamil
Non-Executive Director
92,486 -25.3%
59.05
US$1,041,116 		92,486 -25.3% 59.05 US$1,041,116
2026-06-22 2026-06-22 PrS Proposed sale
3.2
Ali-Jackson Kamil

Director

Non-Executive Director
79,403
218.19
US$2,167,933 		79,403 218.19 US$2,167,933
2026-06-22 2026-06-22 PrS Proposed sale
3.2
Ali-Jackson Kamil

Director

Non-Executive Director
93,815
177.27
US$2,313,490 		93,815 177.27 US$2,313,490
2026-05-28 2026-05-26 PlS Planned sale
3.2
Ali-Jackson Kamil
Non-Executive Director
2,500 -16.5%
29.17
US$72,925 		2,500 -16.5% 29.17 US$72,925
2026-05-26 2026-05-26 PrS Proposed sale
3.2
Ali-Jackson Kamil

Director

Non-Executive Director
2,500
29.17
US$72,925 		2,500 29.17 US$72,925
2026-02-24 2026-02-20 S Sale
3.0
MOOS WALTER H
Non-Executive Director
4,000 -23.9%
36.36
US$145,440 		4,000 -23.9% 36.36 US$145,440
2026-02-20 2026-02-20 PrS Proposed sale
3.0
MOOS WALTER H

Director

Non-Executive Director
4,000
36.36
US$145,440 		4,000 36.36 US$145,440
2025-02-06 2025-02-05 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
1,796 -3.4%
21.93
US$39,379 		1,796 -3.4% 21.93 US$39,379
2025-02-06 2025-02-05 S Sale
3.1
Furey Raymond J.

EVP, GC, CCO & Corp Sec

Officer
1,339 -3.3%
21.93
US$29,359 		1,339 -3.3% 21.93 US$29,359
2025-02-06 2025-02-05 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
4,400 -1.8%
21.93
US$96,474 		4,400 -1.8% 21.93 US$96,474
2025-02-06 2025-02-05 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
1,734 -2.9%
21.93
US$38,020 		1,734 -2.9% 21.93 US$38,020
2025-02-05 2025-02-05 PrS Proposed sale
3.4
Santos David A

Officer

Officer
1,796
21.93
US$39,379 		1,796 21.93 US$39,379
2025-02-05 2025-02-05 PrS Proposed sale
2.6
Schorno Dean L

Officer

Officer
1,734
21.93
US$38,020 		1,734 21.93 US$38,020
2025-02-05 2025-02-05 PrS Proposed sale
3.1
Furey Raymond J.

Officer

Officer
1,339
21.93
US$29,359 		1,339 21.93 US$29,359
2025-02-05 2025-02-05 PrS Proposed sale
4.1
RODRIGUEZ RAUL R

Officer; Director

Executive Director
4,400
21.93
US$96,474 		4,400 21.93 US$96,474
2025-02-06 2025-02-04 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
2,125 -3.8%
20.92
US$44,457 		2,125 -3.8% 20.92 US$44,457
2025-02-06 2025-02-04 S Sale
3.1
Furey Raymond J.

EVP, GC, CCO & Corp Sec

Officer
1,448 -3.5%
20.92
US$30,294 		1,448 -3.5% 20.92 US$30,294
2025-02-06 2025-02-04 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
4,952 -2.0%
20.92
US$103,601 		4,952 -2.0% 20.92 US$103,601
2025-02-06 2025-02-04 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
2,036 -3.3%
20.92
US$42,595 		2,036 -3.3% 20.92 US$42,595
2025-02-04 2025-02-04 PrS Proposed sale
2.6
Schorno Dean L

Officer

Officer
2,036
20.92
US$42,596 		2,036 20.92 US$42,596
2025-02-04 2025-02-04 PrS Proposed sale
4.1
RODRIGUEZ RAUL R

Officer; Director

Executive Director
4,952
20.92
US$103,602 		4,952 20.92 US$103,602
2025-02-04 2025-02-04 PrS Proposed sale
3.1
Furey Raymond J.

Officer

Officer
1,448
20.92
US$30,294 		1,448 20.92 US$30,294
2025-02-04 2025-02-04 PrS Proposed sale
3.4
Santos David A

Officer

Officer
2,125
20.92
US$44,458 		2,125 20.92 US$44,458
2025-01-24 2025-01-24 PrS Proposed sale
Masuda Esteban

Officer

Officer
4,999
22.14
US$110,678 		4,999 22.14 US$110,678
2024-02-06 2024-02-05 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
30,545 -1.5%
1.14
US$34,821 		30,545 -1.5% 1.14 US$34,821
2024-02-06 2024-02-05 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
7,027 -1.7%
1.14
US$8,011 		7,027 -1.7% 1.14 US$8,011
2024-02-06 2024-02-05 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
8,918 -2.5%
1.14
US$10,167 		8,918 -2.5% 1.14 US$10,167
2024-02-06 2024-02-02 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
22,349 -1.1%
1.13
US$25,261 		22,349 -1.1% 1.13 US$25,261
2024-02-06 2024-02-02 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
5,601 -1.3%
1.13
US$6,327 		5,601 -1.3% 1.13 US$6,327
2024-02-06 2024-02-02 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
5,601 -1.5%
1.13
US$6,329 		5,601 -1.5% 1.13 US$6,329
2023-02-07 2023-02-06 S Sale
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
20,340 -1.2%
1.75
US$35,595 		20,340 -1.2% 1.75 US$35,595
2023-02-06 2023-02-02 S Sale
2.6
Schorno Dean L

EVP & Chief Financial Officer

Officer
5,389 -2.7%
1.66
US$8,946 		5,389 -2.7% 1.66 US$8,946
2023-02-06 2023-02-02 S Sale
3.4
Santos David A

EVP, Chief Commercial Officer

Officer
5,388 -3.6%
1.66
US$8,945 		5,388 -3.6% 1.66 US$8,945
2023-02-06 2023-02-02 S Sale
3.1
Dummer Wolfgang

EVP & CMO

Officer
5,389 -6.9%
1.66
US$8,946 		5,389 -6.9% 1.66 US$8,946
2022-06-13 2022-06-09 B Purchase
4.1
RODRIGUEZ RAUL R

CEO, President

Executive Director
1,000,000 +255.2%
0.69
US$688,400 		1,000,000 +255.2% 0.69 US$688,400
2019-05-23 2019-05-22 B Purchase
2.6
Schorno Dean L

EVP &Chief Financial Officer

Officer
3,274 +7.0%
2.13
US$6,971 		3,274 +7.0% 2.13 US$6,971
2019-05-23 2019-05-22 B Purchase
2.6
Schorno Dean L

EVP &Chief Financial Officer

Officer
46,726 +inf%
2.13
US$99,573 		46,726 +inf% 2.13 US$99,573
2018-10-16 2018-10-12 PlS Planned sale Cabatuan Nelson

Principal Accounting Officer

Officer
10,000 -99.4%
3.12
US$31,200 		10,000 -99.4% 3.12 US$31,200
2018-09-19 2018-09-17 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer

Officer
37,500 -100.0%
3.50
US$131,250 		37,500 -100.0% 3.50 US$131,250
2018-09-19 2018-09-17 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer

Officer
115,500 -100.0%
3.50
US$404,250 		115,500 -100.0% 3.50 US$404,250
2018-09-12 2018-09-11 B Purchase Mayer Eldon C. III

EVP & Chief Commercial Officer

Officer
50,000 +30.3%
3.23
US$161,340 		50,000 +30.3% 3.23 US$161,340
2018-09-12 2018-09-10 B Purchase Mayer Eldon C. III

EVP & Chief Commercial Officer

Officer
50,000 +43.5%
3.28
US$164,210 		50,000 +43.5% 3.28 US$164,210
2018-09-06 2018-09-04 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer

Officer
16,500 -100.0%
3.51
US$57,861 		16,500 -100.0% 3.51 US$57,861
2018-08-27 2018-08-23 PP Planned purchase Mayer Eldon C. III

EVP & Chief Commercial Officer

Officer
100,000 +666.7%
2.82
US$282,320 		100,000 +666.7% 2.82 US$282,320
2018-08-21 2018-08-17 PP Planned purchase RODRIGUEZ RAUL R

CEO, President

Executive Director
114,000 +191.5%
2.63
US$300,002 		114,000 +191.5% 2.63 US$300,002
2018-07-05 2018-07-02 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer

Officer
5,000 -100.0%
2.79
US$13,932 		5,000 -100.0% 2.79 US$13,932
2018-04-24 2018-04-20 PlS Planned sale Duliege Anne-Marie

EVP & Chief Medical Officer
5,000 -100.0%
4.11
US$20,550 		5,000 -100.0% 4.11 US$20,550
2017-11-07 2017-11-03 PlS Planned sale Maynard Ryan D

EVP & CFO
100,000 -100.0%
3.90
US$390,000 		100,000 -100.0% 3.90 US$390,000
2017-07-07 2017-07-05 PlS Planned sale Duliege Anne-Marie

Chief Medical Officer

Officer
5,000 -100.0%
2.69
US$13,427 		5,000 -100.0% 2.69 US$13,427
2017-01-13 2017-01-03 PlS Planned sale Duliege Anne-Marie

Chief Medical Officer

Officer
5,000 -100.0%
2.41
US$12,028 		5,000 -100.0% 2.41 US$12,028
2016-09-01 2016-08-30 PlS Planned sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
5,303 -9.1%
4.00
US$21,214 		5,303 -9.1% 4.00 US$21,214
2015-06-12 2015-06-10 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
41,666 -41.7%
3.68
US$153,214 		41,666 -41.7% 3.68 US$153,214
2015-04-03 2015-04-01 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
10,000 -14.6%
3.75
US$37,518 		10,000 -14.6% 3.75 US$37,518
2014-09-05 2014-09-03 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
20,000 -22.6%
2.56
US$51,200 		20,000 -22.6% 2.56 US$51,200
2014-02-26 2014-02-24 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
20,000 -18.5%
3.71
US$74,238 		20,000 -18.5% 3.71 US$74,238
2013-11-20 2013-11-19 S Sale BVF PARTNERS L P/IL

See Explanation of Responses

Large shareholder
153,056 -19.1%
2.64
US$404,343 		153,056 -19.1% 2.64 US$404,343
2013-11-20 2013-11-19 S Sale BVF PARTNERS L P/IL

See Explanation of Responses

Large shareholder
331,566 -22.8%
2.64
US$875,931 		331,566 -22.8% 2.64 US$875,931
2013-06-11 2013-06-07 B Purchase BVF PARTNERS L P/IL

See Explanation of Responses

Large shareholder
8,102 +1.0%
3.47
US$28,095 		8,102 +1.0% 3.47 US$28,095
2013-06-11 2013-06-07 B Purchase BVF PARTNERS L P/IL

See Explanation of Responses

Large shareholder
24,598 +1.7%
3.47
US$85,298 		24,598 +1.7% 3.47 US$85,298
2012-09-14 2012-09-13 S Sale VANCE DOLLY

EVP Corp. Affairs, G.C., Sect.

Officer
4,151 -79.0%
10.43
US$43,284 		4,151 -79.0% 10.43 US$43,284
2012-09-11 2012-09-10 S Sale Maynard Ryan D

EVP & CFO

Officer
17,586 -100.0%
10.52
US$184,927 		17,586 -100.0% 10.52 US$184,927
2012-09-14 2012-09-07 S Sale Maynard Ryan D

EVP & CFO

Officer
23,302 -100.0%
10.67
US$248,560 		23,302 -100.0% 10.67 US$248,560
2012-09-11 2012-09-07 S Sale Maynard Ryan D

EVP & CFO

Officer
34,112 -100.0%
10.55
US$359,960 		34,112 -100.0% 10.55 US$359,960
2012-08-09 2012-08-07 S Sale Maynard Ryan D

EVP & CFO

Officer
300 -100.0%
10.63
US$3,188 		300 -100.0% 10.63 US$3,188
2012-08-09 2012-08-07 S Sale Maynard Ryan D

EVP & CFO

Officer
600 -66.7%
10.62
US$6,372 		600 -66.7% 10.62 US$6,372
2012-08-09 2012-08-07 S Sale Maynard Ryan D

EVP & CFO

Officer
100 -10.0%
10.61
US$1,061 		100 -10.0% 10.61 US$1,061
2012-08-09 2012-08-07 S Sale Maynard Ryan D

EVP & CFO

Officer
700 -41.2%
10.60
US$7,420 		700 -41.2% 10.60 US$7,420
2012-06-20 2012-06-19 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
100 -0.1%
8.71
US$871 		100 -0.1% 8.71 US$871
2012-06-20 2012-06-19 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
9,700 -8.2%
8.70
US$84,390 		9,700 -8.2% 8.70 US$84,390
2012-06-20 2012-06-19 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
100 -0.1%
8.72
US$872 		100 -0.1% 8.72 US$872
2012-06-20 2012-06-19 S Sale PAYAN DONALD G

EVP, Pres. Discovery&Research

Executive Director
100 -0.1%
8.75
US$875 		100 -0.1% 8.75 US$875
2011-06-07 2011-05-26 B Purchase Flynn James E Large shareholder
301,424 +10.4%
8.00
US$2,411,392 		301,424 +10.4% 8.00 US$2,411,392
2011-06-07 2011-05-26 B Purchase Flynn James E Large shareholder
229,252 +11.2%
8.00
US$1,834,016 		229,252 +11.2% 8.00 US$1,834,016
2011-06-07 2011-05-26 B Purchase Flynn James E Large shareholder
72,800 +10.6%
8.00
US$582,400 		72,800 +10.6% 8.00 US$582,400
2011-06-07 2011-05-26 B Purchase Flynn James E Large shareholder
46,524 +11.0%
8.00
US$372,192 		46,524 +11.0% 8.00 US$372,192
Explore more

More insider trading research around Rigel Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America